Pfizer is no longer a pandemic cash machine. It is a large-cap drugmaker trying to prove that a rebuilt commercial book can outrun the next loss-of-exclusivity cycle. The second-quarter print, covering the period ended June 28, 2026, showed launched and acquired products growing at a double-digit operational pace while the Covid franchise nearly vanished from the run rate. Management raised the midpoint of full-year revenue guidance even after cutting the Covid contribution, which is the cleanest signal that the non-pandemic engine is doing real work.
The tension sits underneath that beat. Eliquis, the Vyndaqel family, and Padcev carried demand, yet a $4.3 billion impairment after sigvotatug vedotin missed in previously treated lung cancer reminded holders that pipeline optionality is not a substitute for in-line cash. Adjusted earnings of $0.77 held roughly flat while reported results swung to a small loss, so the operating story and the GAAP story are not the same object. Cost-realignment savings and a still-elevated dividend yield are what keep the equity from being priced as a melting ice cube.
Whether that setup is cheap or merely cheap for a reason depends on three variables. First, whether launched and acquired products keep growing fast enough to offset Eliquis, Ibrance, and Xtandi as exclusivity fades. Second, whether berobenatide and the Seagen-plus-Innovent oncology book produce late-stage evidence before the next cliff year arrives in force. Third, whether free cash flow continues to cover the dividend as leverage stays near current levels. The coming reporting periods resolve the first of those three more than the second.